Diagnostic Evaluation of Malignant Head and Neck Cancer by F-18-FDG PET Compared to CT/MRI

B. Nowak; E. Di Martino; S. Jänicke; U. Cremerius; G. Adam; M. Zimny; P. Reinartz; U. Büll

doi:10.1055/s-0038-1632228

Nuklearmedizin - NuclearMedicine, Table of Contents

Nuklearmedizin 1999; 38(08): 312-318
DOI: 10.1055/s-0038-1632228

Original Article

Schattauer GmbH

Diagnostic Evaluation of Malignant Head and Neck Cancer by F-18-FDG PET Compared to CT/MRI

Diagnostik maligner Kopf-Hals-Tumoren durch F-18-FDG PET im Vergleich zu CT/MRT

Authors

B. Nowak

¹Departments of Nuclear Medicine, Otorhinolaryngology, Plastic Head and Neck Surgery
E. Di Martino

²Otorhinolaryngology, Plastic Head and Neck Surgery
S. Jänicke

³Oral, Maxillofacial and Facial Plastic Surgery
U. Cremerius

¹Departments of Nuclear Medicine, Otorhinolaryngology, Plastic Head and Neck Surgery
G. Adam

⁴Diagnostic Radiology, University Hospital. Aachen University of Technology, Germany
M. Zimny

¹Departments of Nuclear Medicine, Otorhinolaryngology, Plastic Head and Neck Surgery
P. Reinartz

¹Departments of Nuclear Medicine, Otorhinolaryngology, Plastic Head and Neck Surgery
U. Büll

¹Departments of Nuclear Medicine, Otorhinolaryngology, Plastic Head and Neck Surgery

Abstract

Summary

Aim: Evaluation of F-18-FDG PET in comparison to CT/MRI as diagnostic tool in primary and recurrent head and neck cancer. Methods: 78 F-18-FDG PET studies were performed in 71 patients with known or suspected primary (n=48) or recurrent (n=30) head and neck cancer and compared to CT (n=75) or MRI investigations (n=3) concerning detection of the primary or recurrent tumor and detection of regional lymph node metastases in the ipsilateral and contralateral neck sides. Glucose uptake (SUV) of PET findings was correlated to tumor location, grading and dignity of the lesion. Results: Sensitivity and specificity for PET in detection of primary tumors were 87%* and 67%, respectively (CT/MRI 67%* and 44%) (*p<0.05), in detection of local recurrence 86% and 75%, respectively (CT/MRI 57% and 92%), in detection of necks affected by lymph node metastases 80% and 92%, respectively (CT/MRI 80% and 84%). Laryngeal, buccal (cheek) and salivary gland tumors had significant lower glucose uptake (SUV) when compared to tumors of the hypopharynx (p<0.05). G1-tumors (mean SUV 4.26) had significant (p<0.05) lower glucose uptake when compared to G2- and G3-tumors (mean SUV 7.73 and 8.19, respectively). Mean SUV of malignant PET findings (7.88) was significant (p<0.05) higher than mean SUV of benign PET findings (5.70). However, a SUV threshold to improve diagnostic accuracy could not be defined. Conclusion: F-18-FDG PET is significantly more accurate than CT/MRI for detection of head and neck cancer. Both methods are valuable for detection of cervical lymph node metastases. Glucose uptake shows correlation to histological grading. A quantitative SUV analysis does not improve diagnostic accuracy.

Zusammenfassung

Ziel: Evaluation der F-18-FDG-PET in der Primär- und Rezidivdiagnostik von Kopf-Hals-Tumoren im Vergleich zur CT/MRT. Methoden: Es wurden 78 F-18-FDG-PET-Untersuchungen bei 71 Patienten mit gesichertem odervermutetem primärem (n=48) oder rezidiviertem (n=30) Kopf-Hals-Tumor durchgeführt und mit CT- (n=75) bzw. MRT-Untersuchungen (n=3) hinsichtlich des Nachweises des Primärtumors bzw. des Lokalrezidivs sowie von Lymphknotenmetastasen in den ipsi- und kontralateralen Halsseiten verglichen. Der Glukose-Uptake (SUV) der PET-Herdbefunde wurde korreliert zu Tumorlokalisation, Grading sowie zur Dignität der Befunde. Ergebnisse: Sensitivitäten und Spezifitäten der PET betrugen zum Nachweis des Primärtumors 87%* bzw. 67% (CT/MRT 67%* bzw. 44%) (*p<0,05), zum Lokalrezidivnachweis 86% bzw. 75% (CT/MRT 57% bzw. 92%), zur Erkennung von Lymphknotenmetastasen der Halsseiten 80% bzw. 92% (CT/MRT 80% bzw. 84%). Larynx- und Wangen/Speicheldrüsentumoren wiesen signifikant niedrigere SUVWerte auf als Hypopharynxtumoren (p<0,05). Der Glukosemetabolismus war bei G1-Tumorherden (mittlerer SUV 4,26) signifikant (p<0,05) niedriger als bei G2- und G3-Tumorherden (mittlerer SUV 7,73 bzw. 8,19). Der SUV-Mittelwert maligner PET-Herdbefunde (7,88) war signifikant (p<0,05) höher als der benigner PET-Herdbefunde (5,70), ein SUVSchwellenwert zur Verbesserung der diagnostischen Genauigkeit konnte jedoch nicht definiert werden. Schlußfolgerung: F-18-FDG-PET ist signifikant genauer als CT/MRT beim Nachweis von Kopf-Hals-Tumoren. Beide Verfahren eignen sich in gleicher Weise zur Detektion von Halslymphknotenmetastasen. Der Glukose-Uptake korreliert zum histologischen Grading. Eine quantitative SUV-Analyse führt nicht zur Verbesserung der diagnostischen Genauigkeit.

Key words

Head and neck cancer - F-18-FDG PET - computerized tomography - magnetic resonance imaging - grading

Schlüsselwörter

Kopf-Hals-Tumor - F-18-FDG-PET Computertomographie - Magnetresonanztomographie - Grading

Full Text

References

REFERENCES
1 AAssar OS, Fischbein NJ, Caputo GR. et al. Metastatic head and neck cancer: role and usefulness of FDG PET in locating occult primary tumors. Radiology 1999; 210: 177-81.
2 Adams S, Baum RP, Stuckensen T. et al. Prospective comparison of 18F-FDG PET with conventional imaging modalities (CT. MRI, US) in lymph node staging of head and neck cancer. Eur J Nucl Med 1998; 25: 1255-60.
3 Anzai Y, Carroll WR, Quint DJ. et al. Recurrence of head and neck cancer after surgery or irradiation: prospective comparison of 2-deoxy-2-[F-18]fluoro-D-glucose PET and MR imaging diagnoses. Radiology 1996; 200: 135-41.
4 Bailet JW, Abemayor E, Jabour BA. et al. Positron emission tomography: a new, precise imaging modality for detection of primary head and neck tumors and assessment of cervical adenopathy. Laryngoscope 1992; 102: 281-8.
5 Bailet JW, Sercarz JA, Abemayor E. et al. The use of positron emission tomography for early detection of recurrent head and neck squamous cell carcinoma in postradiotherapy patients. Laryngoscope 1995; 105: 135-9.
6 Benchaou M, Lehmann W, Slosman DO. et al. The role of FDG-PET in the preoperative assessment of N-staging in head and neck cancer. Acta Otolaryngol (Stockh) 1996; 116: 332-5.
7 Braams JW, Pruim J, Freiing NJM. et al. Detection of lymph node metastases of squamous-cell cancer of the head and neck with FDG-PET and MRI. J Nucl Med 1995; 36: 211-6.
8 Braams JW, Pruim J, Kole AC. et al. Detection of unknown primary head and neck tumors by positron emission tomography. Int J Oral Maxillofac Surg 1997; 26: 112-5.
9 Cremerius U, Striepecke E, Henn W. et al. 18FDG-PET in intracranial meningiomas versus grading, proliferation index, cellular density and cytogenetical analysis. Nuklearmedizin 1994; 33: 144-9.
10 Di Chiro G. Positron emission tomography using [18F]fluorodeoxyglucose in brain tumors: a powerful diagnostic and prognostic tool. Invest Radiol 1986; 22: 360-71.
11 Eichhorn T, Schroeder HG, Glanz H, Schwerk WB. Histologically controlled comparison of palpation and sonography in the diagnosis of cervical lymph node metastases. Laryngol Rhinol Otol 1987; 66: 266-74.
12 Feinmesser R, Freeman JL, Feinmesser M. et al. Role of modern imaging in decision-making for elective neck dissection. Head Neck 1992; 14: 173-6.
13 Fischbein NJ, AAssar OS, Caputo GR. et al. Clinical utility of positron emission tomography with 18F-fluorodeoxyglucose in detecting residual/recurrent squamous cell carcinoma of the head and neck. Am J Neuroradiol 1998; 19: 1189-96.
14 Glazer H, Niemeyer JH. Blafer DM. Neck neoplasms: MRI imaging part I. Initial evaluation. Radiology 1986; 160: 343-8.
15 Greven KM, Williams III DW, Keyes Jr JW. et al. Positron emission tomography of patients with head and neck carcinoma before and after high dose irradiation. Cancer 1994; 74: 1355-9.
16 Greven KM, Williams DW, 3rd. Keyes Jr JW. et al Can positron emission tomography distinguish tumor recurrence from irradiation sequelae in patients treated for larynx cancer?. Cancer J Sei Am 1997; 3: 353-7.
17 Griffeth LK, Dehdashti F, McGuire AH. et al. PET evaluation of soft tissue masses with fluorine-18 fluoro-2-deoxy-D-glucose. Radiology 1992; 182: 185-94.
18 Haberkorn U, Strauss LG, Reisser Ch. et al. Glucose uptake, perfusion, and cell proliferation in head and neck tumors: relation of positron emission tomography to flow cytometry. J Nucl Med 1991; 32: 1548-55.
19 Jabour BA, Choi Y, Höh CK. et al. Extracranial head and neck: PET imaging with 2-[F-18]fluoro-2-deoxy-D-glucose and MR imaging correlation. Radiology 1993; 186: 27-35.
20 Kole AC, Nieweg OE, Pruim J. et al. Detection of unknown occult primary tumors using positron emission tomography. Cancer 1998; 82: 1160-6.
21 Landis SH, Murray T, Bolden S, Wingo PA. Cancer Statistics, 1999. Ca Cancer J Clin 1999; 49: 8-31.
22 Lapela M, Grenman R, Kurki T. et al. Head and neck cancer: detection of recurrence with PET and 2-[F-18]fluoro-2-deoxy-D-glucose. Radiology 1995; 197: 205-11.
23 Laubenbacher C, Saumweber D, Wagner-Manslau C. et al. Comparison of fluorine-18-fluorodeoxyglucose PET, MRI and endoscopy for staging head and neck squamous-cell carcinomas. J^Nucl Med 1995; 36: 1747-57.
24 Laubenbacher C, Kau RJ, Alexiou C. et al. Kopf-Hals-Tumoren. In: PET in der Onkologie: Grundlagen und klinische Anwendungen. Ruhlmann J, Oehr P, Biersack H-J. (Hrsg.). Berlin, Heidelberg: Springer; 1998: 64-77.
25 Lenz M, Bongers H, Ozdoba C, Skalej M. The clinical value of computed tomography in the pretherapeutic T-staging of orofacial tumors. RöFo Fortschr Geb Röntgenstr Neuen Bildgeb Verfahr 1989; 151: 138-44.
26 McGuirt WF, Williams III DW, Keyes Jr JW. et al. A comparative diagnostic study of head and neck nodal metastases using positron emission tomography. Laryngoscope 1995; 105: 373-5.
27 McGuirt WF, Greven K, Keyes Jr JW. et al. Laryngeal radionecrosis versus recurrent cancer: a clinical approach. Ann Otol Rhinol Laryngol 1998; 107: 293-6.
28 McGuirt WF, Greven K, Williams D. 3rd et al. PET scanning in head and neck oncology: a review. Head Neck 1998; 20: 208-15.
29 Minn H, Joensuu H, Ahonen A, Klemi P. Fluorodeoxyglucose imaging: a method to assess the proliferative activity of human cancer in vivo. Cancer 1988; 61: 1776-81.
30 Minn H, Lapela M, Klemi PJ. et al. Prediction of survival with fluorine-18-fluoro-deoxyglucose and PET in head and neck cancer. J Nucl Med 1997; 38: 1907-11.
31 Myers LL, Wax MK, Nabi H. et al. Positron emission tomography in the evaluation of the NO neck. Laryngoscope 1998; 108: 232-6.
32 Nitzsche EU, Hoegerle S, Juengling F. et al. Nichtinvasive Dignitätsbestimmung von Pankreasläsionen mittels FDG-PET: Ist eine Beurteilung der FDG-Kinetik gegenüber der statischen Analyse von Vorteil?. Nuklearmedizin 1998; 37 A 11.
33 Rege S, Maass A, Chaiken L. et al. Use of positron emission tomography with fluorodeoxyglucose in patients with extracranial head and neck cancers. Cancer 1994; 73: 3047-58.
34 Reske SN, Bares R, Büll U. et al. Clinical value of positron emission tomography (PET) in oncologic questions: results of an interdisciplinary consensus conference. Nuklearmedizin 1996; 35: 42-52.
35 Reske SN. et al. Konsensus – Onko-PET. Nuklearmedizin 1997; 36: 45-6.
36 Scheidhauer K, Jungehülsing M, Pietrzyk U, Schicha H. FDG-PET zum Nachweis unbekannter Primärtumoren (CUP-Syndrom). Nuklearmedizin 1998; 37 A 11.
37 Schipper JH, Schräder M, Arweiler D. et al. Positron emission tomography for primary tumor detection in lymph node metastases with unknown primary tumor. HNO 1996; 44: 254-7.
38 Som PM. Detection of metastasis in cervical lymph nodes: CT and MR criteria and differential diagnosis. Am J Roentgenol 1992; 156: 961-9.
39 Spitz MR. Epidemiology and risk factors for head and neck cancer. Sem Oncol 1994; 21: 281-8.
40 Steiner W. Early detection of cancer in the upper aerodigestive tract. Part I. HNO 1993; 41: 360-7.
41 Steinkamp HJ, Maurer J, Heim T. et al. Magnetic resonance tomography and computerized tomography in tumor staging of mouth and oropharyngeal cancer. HNO 1993; 41: 519-25.
42 Thill R, Neuerburg J, Fabry U. et al. Comparison of findings with 18-FDG PET and CT in pretherapeutic staging of malignant lymphoma. Nuklearmedizin 1997; 36: 234-9.
43 Vokes EE, Weichselbaum RR, Lippman SM, Hong WK. Medical progress: head and neck cancer. N Engl J Med 1993; 328: 184-94.